<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: tpiv.xfr; Date: 2015%2D06%2D19T17:26:56 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:tpiv="http://tapimmune.com/20150331">
    <link:schemaRef xlink:href="tpiv-20150331.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_MinimumMember_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-30_us-gaap_MaximumMember_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-03-31_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:SharePurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_FairValueHedging1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">tpiv:FairValueHedging1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueHedgingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_FairValueHedgingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tpiv:ConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable22Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable21Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_ConvertibleNotesPayableMember10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable3Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable4Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable5Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable6Member10354410">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable12Member10354425">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable16Member10354441">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable18Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable19Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable20Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable20Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable21Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable21Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable22Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tpiv:ConvertibleNotesPayable22Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OIfficerAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:OIfficerAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OIfficerAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">tpiv:OIfficerAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesAWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesAWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesBWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesBWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesCWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesCWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesDWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesDWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SeriesEWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tpiv:SeriesEWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchNineTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_MarchNineTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchNineTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:JanuaryTwelveTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchTwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">tpiv:MarchTwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Patients">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>tpiv:Patients</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>tpiv:Number</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-03-31" unitRef="Shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1465712</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">20318815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-03-31" unitRef="Shares" decimals="INF">32638811</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1465712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">20318815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-03-31" unitRef="Shares" decimals="INF">32638811</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-8768003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-1023636</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">-1765596</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">46715500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-55426635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-58334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">20319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">43912427</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">85265776</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-49894083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-86309731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-61648</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2015-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="INF">32639</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">85493220</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="INF">-87291455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2015-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1250000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1250000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2015-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <tpiv:ConvertiblePreferredStockSharesDesignated contextRef="AsOf2015-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1250000</tpiv:ConvertiblePreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2015-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2015-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2015-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2015-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">48589</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">141944</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">1453505</us-gaap:Cash>
    <tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">210000</tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount>
    <tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">210000</tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount>
    <tpiv:ConvertibleNotesPromissoryNotesLoanAndAccruedInterestConvertedIntoCommonStockAmount contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4349428</tpiv:ConversionOfAccountsPayableToCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="INF">1836</tpiv:ConversionOfAccountsPayableToCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">4347592</tpiv:ConversionOfAccountsPayableToCommonStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ConversionOfAccountsPayableToCommonStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">77032</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">224448</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">1536009</us-gaap:AssetsCurrent>
    <us-gaap:PostconfirmationDeferredFinancingCosts contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">13439</us-gaap:PostconfirmationDeferredFinancingCosts>
    <us-gaap:PostconfirmationDeferredFinancingCosts contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15004</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">82504</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">82504</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">8845035</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1248084</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">3301605</us-gaap:LiabilitiesCurrent>
    <us-gaap:LoansPayable contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">42200</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-582300</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">77032</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">224448</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">1536009</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-58334</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-55426635</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-86309731</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">-87291455</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">46715500</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">85265776</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">85493220</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1466</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">20319</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">32639</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31_us-gaap_SeriesAMember_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2015-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2015-03-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">189000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">22500</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">609378</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">697634</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3181927</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">1164098</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">418786</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1966683</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-52976</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5896</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AccretionOfDiscount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">492296</us-gaap:AccretionOfDiscount>
    <us-gaap:AccretionOfDiscount contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">483636</us-gaap:AccretionOfDiscount>
    <us-gaap:AccretionOfDiscount contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccretionOfDiscount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">1110831</us-gaap:AccretionOfDiscount>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">581</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-338297</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">46440</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1546257</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">58334</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-1249</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">3314</us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-30824762</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-29708479</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-981724</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-5529238</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">-2.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-03-31" unitRef="USDPShares" decimals="INF">-3.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-03-31" unitRef="USDPShares" decimals="INF">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-4.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">15465213</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-03-31" unitRef="Shares" decimals="INF">7631669</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">27611255</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">1136115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-30883096</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-29707230</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-981724</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-5532552</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1391123</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">690000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">3750</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">132093</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-26884231</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-27663430</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">-2560045</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">76367</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-145199</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">158913</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">9961</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1835315</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">24013</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-67500</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-2187145</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-372954</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-1014453</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-694583</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">32200</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1877500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="INF">2326014</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2280500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">418000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">2326014</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">709333</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">93355</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">45046</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">1311561</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">14750</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">369000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">369000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">525000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">476000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">58334</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:NoncashInterestAndFinanceCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">83247</tpiv:NoncashInterestAndFinanceCharges>
    <tpiv:NoncashInterestAndFinanceCharges contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">483636</tpiv:NoncashInterestAndFinanceCharges>
    <tpiv:NoncashInterestAndFinanceCharges contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <tpiv:NoncashInterestAndFinanceCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">645562</tpiv:NoncashInterestAndFinanceCharges>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2415000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">513000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">558000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">42000</us-gaap:IncreaseDecreaseInNotesPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">42000</us-gaap:IncreaseDecreaseInNotesPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedParties contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1465712</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">764029</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20318816</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2015-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">32638811</us-gaap:SharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">412047</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1477587</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">412</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1477175</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">3750</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">46840</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">46840</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2015-01-01to2015-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">3750</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">31891</tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements>
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">31891</tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements>
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ObligationToIssueSharesAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">264649</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreements>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1211627</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">265</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1211362</tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToDebtSettlementAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-11300</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">-11300</tpiv:FindersFee>
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:FindersFee contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToServiceAgreements contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3500</tpiv:IssuedAtFairValuePursuantToServiceAgreements>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">38936</tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">38932</tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount>
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:IssuedAtFairValuePursuantToServiceAgreementsAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensation contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">811000</tpiv:SharesIssuedForDirectorCompensation>
    <tpiv:SharesIssuedForDirectorCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2500</tpiv:SharesIssuedForDirectorCompensation>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1391123</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">8176</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">811</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1390312</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="INF">3</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">8173</tpiv:SharesIssuedForDirectorCompensationAmount>
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:SharesIssuedForDirectorCompensationAmount contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:NoncashExerciseOfWarrants contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">18986</tpiv:NoncashExerciseOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-30883096</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-981724</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-5532552</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="INF">-30883096</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="INF">-5532552</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2015-01-01to2015-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="INF">-981724</us-gaap:ProfitLoss>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStock contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14048701</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStock>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">30951078</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">14049</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount>
    <tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30937029</tpiv:ConvertibleNotesPromissoryNotesLoanPayablerelatedPartyDueToRelatedPartiesAndAccruedInterestConvertedIntoSeriesAndBPreferredStockAndImmediatelyConvertedIntoCommonsStockAmount>
    <tpiv:ConversionOfAccountsPayableToCommonStock contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1836361</tpiv:ConversionOfAccountsPayableToCommonStock>
    <tpiv:PrivatePlacementNetOfFindersFee contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2157042</tpiv:PrivatePlacementNetOfFindersFee>
    <tpiv:PrivatePlacementNetOfFindersFee contextRef="From2015-01-01to2015-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">12319995</tpiv:PrivatePlacementNetOfFindersFee>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1877500</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">2326014</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2157</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1875343</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2015-01-01to2015-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="INF">12320</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2015-01-01to2015-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">2313694</tpiv:PrivatePlacementNetOfFindersFeeAmount>
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2015-01-01to2015-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <tpiv:PrivatePlacementNetOfFindersFeeAmount contextRef="From2015-01-01to2015-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">58334</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3314</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="INF">58334</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="INF">3314</us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">387500</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">140000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">387500</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-492365</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-492365</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">-492365</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:LoansAndLeasesReceivableCommercial contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-277942</us-gaap:LoansAndLeasesReceivableCommercial>
    <us-gaap:LoansAndLeasesReceivableCommercial contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-52942</us-gaap:LoansAndLeasesReceivableCommercial>
    <us-gaap:LoansAndLeasesReceivableCommercial contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">-52942</us-gaap:LoansAndLeasesReceivableCommercial>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3778401</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">693362</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">703323</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <dei:EntityRegistrantName contextRef="From2015-01-01to2015-03-31">TAPIMMUNE INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2015-01-01to2015-03-31">0001094038</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2015-01-01to2015-03-31">S-1</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2015-01-01to2015-03-31">2015-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2015-01-01to2015-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2015-01-01to2015-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2015-01-01to2015-03-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3161977</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">369346</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-3370927</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-1186598</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-1028164</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-2664317</us-gaap:OperatingIncomeLoss>
    <tpiv:LossOnLawsuit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:LossOnLawsuit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">-103950</tpiv:LossOnLawsuit>
    <tpiv:InterestAndFinanceCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-83247</tpiv:InterestAndFinanceCharges>
    <tpiv:InterestAndFinanceCharges contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">-35269</tpiv:InterestAndFinanceCharges>
    <tpiv:InterestAndFinanceCharges contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <tpiv:InterestAndFinanceCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">-645562</tpiv:InterestAndFinanceCharges>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-581</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">338297</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-46440</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1546257</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <tpiv:AccretionOfInterestOnConvertibleDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">492296</tpiv:AccretionOfInterestOnConvertibleDebt>
    <tpiv:AccretionOfInterestOnConvertibleDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1110831</tpiv:AccretionOfInterestOnConvertibleDebt>
    <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">26884231</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
    <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">27663430</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
    <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">2560045</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">20000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-15000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1450083</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">620826</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1348663</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">201334</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">68448</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">220290</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">558032</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3778401</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">693362</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">492365</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="AsOf2014-12-31" unitRef="Pure" decimals="INF">0.15</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-03-31" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-03-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-04-01to2014-06-30" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-03-31" unitRef="Pure" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-03-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-04-01to2014-06-30" unitRef="Pure" decimals="INF">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-03-31" unitRef="Pure" decimals="INF">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-03-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-04-01to2014-06-30" unitRef="Pure" decimals="INF">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-03-31">P2M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-04-01to2014-06-30">P22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">712000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">708000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="INF">4000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_MinimumMember_custom_SharePurchaseWarrantsMember">P10M6D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-30_us-gaap_MaximumMember_custom_SharePurchaseWarrantsMember">P2Y9M11D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember">P1Y2M19D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember">P3Y6M11D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2015-01-01to2015-03-31_custom_SharePurchaseWarrantsMember">P4Y10M6D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2014-01-01to2014-03-31_custom_SharePurchaseWarrantsMember">P3Y9M29D</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_MinimumMember_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.0013</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-30_us-gaap_MaximumMember_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.0078</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0025</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.011</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-03-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.0137</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-03-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.0065</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-03-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-03-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">1.559</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_custom_SharePurchaseWarrantsMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">190.68</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-03-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">1.55</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-03-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">1.59</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_custom_SharePurchaseWarrantsMember" unitRef="Pure" decimals="INF">1.99</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">582300</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">582300</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset contextRef="AsOf2013-12-31_custom_FairValueHedging1Member" unitRef="USD" decimals="INF">582300</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">722804</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">2053000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">722804</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2013-12-31_custom_FairValueHedging1Member" unitRef="USD" decimals="INF">722804</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueHedgingMember" unitRef="USD" decimals="INF">9000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">9000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2015-03-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2015-03-31_us-gaap_FairValueHedgingMember" unitRef="USD" decimals="INF">2053000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2015-03-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="AsOf2015-03-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">2053000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">140000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">583000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">868000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2012-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">977000</us-gaap:LiabilitiesFairValueDisclosure>
    <tpiv:AdditionsDuringYear contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">2090000</tpiv:AdditionsDuringYear>
    <tpiv:AdditionsDuringYear contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">206000</tpiv:AdditionsDuringYear>
    <tpiv:AdditionsDuringYear contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">811000</tpiv:AdditionsDuringYear>
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="INF">-1096000</us-gaap:UnrealizedGainLossOnDerivativesAndCommodityContracts>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">-714000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">131000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-46000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">-1043000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="INF">-131000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">2053000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">140000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2013-01-01to2013-12-31_custom_ConversionOptionMember" unitRef="USD" decimals="0">583000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2014-01-01to2014-12-31_custom_ConversionOptionMember" unitRef="USD" xsi:nil="true" />
    <tpiv:ExtinguishmentOfDebtAmount1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="INF">9000</tpiv:ExtinguishmentOfDebtAmount1>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">--12-23</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">--02-24</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">--04-04</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">--06-06</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">--08-12</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">--08-20</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">--10-15</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">--11-20</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">--12-18</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">--01-05</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">--01-31</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">--02-27</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">--04-02</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">--04-18</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">--05-02</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">--05-05</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">--05-14</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">--06-27</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">--06-19</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">--07-12</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">--10-18</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">--11-01</tpiv:IssueDates>
    <tpiv:IssueDates contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">--12-19</tpiv:IssueDates>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">--06-23</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">--02-24</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">--04-04</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">--06-06</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">--11-12</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">--08-20</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">--10-15</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">--11-20</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">--12-14</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">--05-31</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">--05-31</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">--02-27</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">--06-02</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">--12-18</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">--05-31</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">--07-05</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">--05-14</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">--06-27</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">--06-19</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">--07-12</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">--04-18</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">--05-01</tpiv:MaturityDate>
    <tpiv:MaturityDate contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">--06-19</tpiv:MaturityDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389" unitRef="Pure" decimals="INF">0.09</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member">&#9;Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember">&#9;Variable at $25.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327">&#9;Variable at $25.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member">&#9;Variable at $25.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member">&#9;Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374">Variable at $12.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389">Fixed at $10.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389">Fixed at $8.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389">Fixed at $4.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405">Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405">Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405">Variable at $3.44</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405">Fixed at $7.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405">Fixed at $6.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405">Variable at $9.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405">Fixed at $3.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421">Variable at $1.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421">Variable at $1.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421">Variable at $1.00</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable22Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable1Member8546327" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable4Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable5Member8546374" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable6Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable7Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable8Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable9Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable10Member8546389" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable11Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable12Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable13Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable14Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable15Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable16Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable17Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable18Member8546405" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable19Member8546421" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable20Member8546421" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2014-01-01to2014-12-31_custom_ConvertibleNotesPayable21Member8546421" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_us-gaap_ConvertibleNotesPayableMember10354410" unitRef="USD" decimals="0">980858</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable1Member" unitRef="USD" decimals="0">215000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable2Member" unitRef="USD" decimals="0">30000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable3Member10354410" unitRef="USD" decimals="0">27500</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable4Member10354410" unitRef="USD" decimals="0">20000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable5Member10354410" unitRef="USD" decimals="0">340000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable6Member10354410" unitRef="USD" decimals="0">10748</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable7Member" unitRef="USD" decimals="0">50000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable8Member" unitRef="USD" decimals="0">452729</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable9Member" unitRef="USD" decimals="0">24135</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable10Member" unitRef="USD" decimals="0">58500</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable11Member" unitRef="USD" decimals="0">80967</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable12Member10354425" unitRef="USD" decimals="0">31688</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable13Member" unitRef="USD" decimals="0">50000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable14Member" unitRef="USD" decimals="0">45000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable15Member" unitRef="USD" decimals="0">126000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable16Member10354441" unitRef="USD" decimals="0">37620</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable17Member" unitRef="USD" decimals="0">32000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable18Member" unitRef="USD" decimals="0">96800</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable19Member" unitRef="USD" decimals="0">94444</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable20Member" unitRef="USD" decimals="0">80000</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable21Member" unitRef="USD" decimals="0">277222</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment contextRef="From2013-01-01to2013-12-31_custom_ConvertibleNotesPayable22Member" unitRef="USD" decimals="0">536400</us-gaap:ProceedsFromPrincipalRepaymentsOnLoansAndLeasesHeldForInvestment>
    <tpiv:TotalConvertibleNotes contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:TotalConvertibleNotes contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">3697611</tpiv:TotalConvertibleNotes>
    <tpiv:UnamortizedNoteDiscount contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:UnamortizedNoteDiscount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">-535634</tpiv:UnamortizedNoteDiscount>
    <tpiv:TotalOnBalanceSheet contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <tpiv:TotalOnBalanceSheet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">3161977</tpiv:TotalOnBalanceSheet>
    <us-gaap:FederalHomeLoanBankAdvancesDiscount contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">42200</us-gaap:FederalHomeLoanBankAdvancesDiscount>
    <us-gaap:FederalHomeLoanBankAdvancesDiscount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:FederalHomeLoanBankAdvancesDiscount>
    <tpiv:InvestorsConverted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">37000</tpiv:InvestorsConverted>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">5200</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2014-01-01to2014-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">12000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <tpiv:OutstandingPrincipalAmount contextRef="From2014-01-01to2014-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">210000</tpiv:OutstandingPrincipalAmount>
    <tpiv:OutstandingPromissoryNotes contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">52942</tpiv:OutstandingPromissoryNotes>
    <tpiv:OutstandingPromissoryNotes contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">277942</tpiv:OutstandingPromissoryNotes>
    <tpiv:OutstandingPromissoryNotes contextRef="From2014-01-01to2014-12-31_custom_OIfficerAndDirectorMember" unitRef="USD" decimals="0">23000</tpiv:OutstandingPromissoryNotes>
    <tpiv:AmountOfPromissoryNotesRepaid contextRef="From2014-01-01to2014-12-31_custom_OIfficerAndDirectorMember" unitRef="USD" decimals="0">15000</tpiv:AmountOfPromissoryNotesRepaid>
    <tpiv:AmountOfPromissoryNotesRepaid contextRef="From2013-01-01to2013-12-31_custom_OIfficerAndDirectorMember" unitRef="USD" decimals="0">0</tpiv:AmountOfPromissoryNotesRepaid>
    <us-gaap:NotesPayable contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">369000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:NotesPayable>
    <tpiv:PreferredStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">1250000</tpiv:PreferredStock>
    <tpiv:PreferredStock contextRef="From2014-01-01to2014-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="Shares" decimals="INF">1500000</tpiv:PreferredStock>
    <tpiv:PreferredStock contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">265000</tpiv:PreferredStock>
    <us-gaap:CommonStockDividendsShares contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">811000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">100000</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockDividendsShares contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">1886792</us-gaap:CommonStockDividendsShares>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">954000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">105000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">5250</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:ManagementFeeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">15000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">132093</us-gaap:ManagementFeeExpense>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-1265000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1321000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-1265000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1321000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1265000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1321000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">9174000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10433000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tpiv:DeferredTaxStockBasedCompensation contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1866000</tpiv:DeferredTaxStockBasedCompensation>
    <tpiv:DeferredTaxStockBasedCompensation contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1871000</tpiv:DeferredTaxStockBasedCompensation>
    <tpiv:DeferredTaxTechnologyLicensingFee contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">167000</tpiv:DeferredTaxTechnologyLicensingFee>
    <tpiv:DeferredTaxTechnologyLicensingFee contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">167000</tpiv:DeferredTaxTechnologyLicensingFee>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">11207000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">12471000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-11207000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-12471000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2415000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <tpiv:ConvertibleCommonStockSharesIssuedUponConversion contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">1836000</tpiv:ConvertibleCommonStockSharesIssuedUponConversion>
    <tpiv:TradingOfSharesAtFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4349000</tpiv:TradingOfSharesAtFairValue>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">14000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <tpiv:LossOnExtinguishment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1934000</tpiv:LossOnExtinguishment>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4116000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">3293000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">738000</us-gaap:ProceedsFromConvertibleDebt>
    <tpiv:ConvertibleNotesNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">418000</tpiv:ConvertibleNotesNet>
    <tpiv:ConvertibleNotesNet contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">418000</tpiv:ConvertibleNotesNet>
    <tpiv:ConvertibleNotesNet contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <tpiv:ConvertibleNotesNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">728000</tpiv:ConvertibleNotesNet>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="INF">30867</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-140504</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-9000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">-2053000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">-140504</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2013-12-31_custom_FairValueHedging1Member" unitRef="USD" decimals="INF">-140504</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueHedgingMember" unitRef="USD" decimals="INF">-9000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2014-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">-9000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-03-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-03-31_us-gaap_FairValueHedgingMember" unitRef="USD" decimals="INF">-2053000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-03-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2015-03-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="INF">-2053000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">140504</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9415</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesDerivatives contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">2052975</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <tpiv:NetLossPerShareApplicableToCommonStockholdersPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Net Loss per Share Applicable to Common Stockholders&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Options, warrants, and convertible debt outstanding were all&#13;considered anti-dilutive for the years ended December 31, 2014 and 2013, due to net losses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities were not included in the diluted net&#13;loss per share calculation because their effect was anti-dilutive as of the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;2,556,133&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;25,168&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;103,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;124,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;738,760&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Excluded potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;2,724,847&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;953,642&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:NetLossPerShareApplicableToCommonStockholdersPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Update No. 2014-10,&#13;&lt;i&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to&#13;Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/i&gt; removes all incremental financial reporting requirements for&#13;development stage entities, including the removal of reporting of the cumulative results of operations and cash flows for the&#13;period from inception to the end of the current period. The update is effective for the first annual period beginning after December&#13;15, 2014. Early adoption is permitted, and the Company has adopted this change effective with its form 10-Q filing for the period&#13;ending September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standard Update No. ASU 2014-15, Presentation of Financial Statements&amp;#151;Going Concern&#13;(Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#146;s Ability to Continue as a Going Concern. The amendments&#13;in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods&#13;thereafter. Early application is permitted. The Company is currently evaluating the impact of this update on its consolidated&#13;financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Loss per Common Share&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per share is computed by dividing loss attributable&#13;to common stockholders by the weighted average number of common shares outstanding for the period. If applicable, diluted earnings&#13;per share reflect the potential dilution of securities that could share in the earnings (loss) of the Company. The common shares&#13;potentially issuable on conversion of outstanding convertible debentures, warrants and stock options are anti-dilutive and have&#13;not been included in the calculation.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Derivative Liability&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates its convertible debt,&#13;options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives&#13;to be separately accounted for in accordance with ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying&#13;amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the&#13;fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as&#13;either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is&#13;marked to fair value at the conversion date and then the related fair value is reclassified to equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In circumstances where the embedded conversion&#13;option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the&#13;convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single,&#13;compound derivative instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The classification of financial instruments,&#13;including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting&#13;period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to&#13;liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified&#13;in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected&#13;within 12 months of the balance sheet date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In evaluating the application of ASC 815-40,&#13;management must determine whether an instrument (or an embedded feature) is indexed to the Company&amp;#146;s own stock. ASC 815-40-15&#13;provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature)&#13;is indexed to its own stock, including evaluating the instrument&amp;#146;s contingent exercise and settlement provisions. The application&#13;of ASC 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features&#13;and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free standing warrants that contain&#13;contingently puttable cash settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated the application&#13;ASC 480-10 &lt;i&gt;Distinguishing liabilities from equity&lt;/i&gt;, ASC 815-40 &lt;i&gt;Contracts in an Entity&amp;#146;s Own Equity&lt;/i&gt; and ASC 718-10&#13;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt; to the issued and outstanding warrants to purchase common stock that were issued&#13;with the convertible notes, private placements, consulting agreements, and various debt settlements during 2009 through 2012. Based&#13;on the guidance, management concluded these instruments are required to be accounted for as derivatives either due to a ratchet&#13;down protection feature available on the exercise price (Note 5) or a holder&amp;#146;s right to put the warrants back to the Company&#13;for cash under certain conditions or a conversion option feature with conversion into variable number of shares. Under ASC 815-40-25,&#13;the Company records the fair value of these warrants and conversion options (derivatives) on its balance sheet, at fair value,&#13;with changes in the values reflected in the Statements of Operations as &amp;#147;Changes in fair value of derivative liabilities&amp;#148;.&#13;The fair value of the share purchase warrants are recorded on the Balance Sheet under &amp;#145;Derivative liability &amp;#150; warrants&amp;#146;&#13;and the fair value of the conversion options are recorded on the Balance Sheet under &amp;#145;Derivative liability &amp;#150; conversion&#13;option&amp;#146;.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income Taxes&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the asset and liability&#13;method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax&#13;consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective&#13;tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable&#13;income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets&#13;and liabilities of a change in tax rates is recognized in income in the period that includes the date of allowances against deferred&#13;tax assets.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and Development Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has acquired development and&#13;marketing rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may&#13;not have alternate future uses and therefore, have been expensed as incurred as research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred Financing Costs&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company defers direct costs incurred&#13;in connection with the sale of common shares which are offset against the proceeds of the financing upon completion. Costs incurred&#13;in connection with convertible loans payable are deferred and amortized as a financing cost over the term of the convertible loans.&#13;Upon conversion of the loan, any unamortized amount of deferred financing costs will be charged to stockholders&amp;#146; equity as&#13;a cost of financing.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-Based Compensation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based compensation is measured at&#13;the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized&#13;as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized&#13;for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is&#13;determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&amp;#160;&amp;#151; The expected&#13;term of options represents the period that the Company&amp;#146;s stock-based awards are expected to be outstanding based on the simplified&#13;method, which is the half-life from vesting to the end of its contractual term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent&#13;remaining term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Expected Dividend&lt;/i&gt;&amp;#160;&amp;#151; The&#13;Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable&#13;future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock&#13;options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <tpiv:PriorPeriodReclassifications contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Prior Period Reclassifications&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior period amounts that were&#13;combined in the December 31, 2013 consolidated financial statements have been reclassified for comparability with the December&#13;31, 2014 presentation. These reclassifications had no effect on previously reported net loss.&lt;/p&gt;</tpiv:PriorPeriodReclassifications>
    <tpiv:PriorPeriodReclassifications contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Prior Period&#13;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Certain prior&#13;period amounts that were combined in the March 31, 2014 consolidated financial statements have been reclassified for comparability&#13;with the March 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.&lt;/p&gt;</tpiv:PriorPeriodReclassifications>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair Value Measurements&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of certain of the Company&amp;#146;s&#13;financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost&#13;because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a&#13;recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values.&#13;Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -14.2pt"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets&#13;and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated&#13;by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -14.2pt"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level&#13;3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets&#13;or liabilities. Financial Instruments and Concentration of Credit Risk.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair values of cash, accounts payable,&#13;and other current monetary liabilities approximate their carrying values due to the immediate or short-term maturity of these financial&#13;instruments. The Company&amp;#146;s operations and financing activities are conducted primarily in United States dollars, and as a&#13;result the Company is not subject to significant exposure to market risks from changes in foreign currency rates. Unless otherwise&#13;noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from assets and&#13;liabilities classified as financial instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Principles of Consolidation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These financial statements include the&#13;accounts of the Company and its wholly-owned subsidiaries GeneMax Pharmaceuticals Inc. (&amp;#147;GPI&amp;#148;) and GeneMax Pharmaceuticals&#13;Canada Inc. (&amp;#147;GPC&amp;#148;). All significant intercompany balances and transactions are eliminated upon consolidation. In the&#13;fourth quarter of fiscal 2014, the Company dissolved GPC and no longer has any Canadian subsidiary.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basis of Presentation&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These financial statements are presented&#13;in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States&#13;of America (&amp;#147;GAAP&amp;#148;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Use of Estimates&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Preparation of the Company&amp;#146;s financial&#13;statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and&#13;disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&amp;#146;s&#13;estimates and assumptions include deferred taxes and related tax balances and disclosures, determining the fair value of stock-based&#13;compensation and stock based transactions, the fair value of the components of the convertible notes payable and accrued liabilities.&#13;Matters impacting the Company&amp;#146;s ability to continue as a going concern and contingencies also involve the use of estimates&#13;and assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following securities were not included in the diluted net&#13;loss per share calculation because their effect was anti-dilutive as of the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,430&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;2,556,133&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;25,168&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;103,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;124,284&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;738,760&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Excluded potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;2,724,847&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;953,642&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Accounts Payable and Accrued Liabilities&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;December 31, 2014 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;December 31, 2013 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$ &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;$ &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Trade accounts payable &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;620,826 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,450,083 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Share-settled debt&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,348,663&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Accrued liabilities &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;68,448 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;201,334 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Employee payroll and severance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;220,290 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;Accrued interest &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;4,088 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;558,032 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td nowrap="nowrap" colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;693,362 &lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;3,778,401&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The inputs utilized in the final mark to&#13;market were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;&lt;b&gt;For the Quarter ending June 30, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"&gt;&lt;b&gt;Total&amp;#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Dividend yield (per share)&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Strike price&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;1.027&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.88&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Volatility (annual)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;199.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;199.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.05&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.05&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Contractual term (years)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.24&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;0.06&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;Fair value of Conversion Option at extinguishment&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;708,000&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"&gt;&lt;b&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;712,000 &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The inputs utilized&#13;in the final mark to market were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Conversion Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Strike price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility (annual)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;199.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value of Conversion Option at extinguishment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;708,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p&gt;&lt;/p&gt;&#13;&#13;&lt;p&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of quantitative information with&#13;respect to valuation methodology and significant unobservable inputs used for the Company&amp;#146;s common stock purchase warrants&#13;that are categorized within Level 3 of the fair value hierarchy for the years ended 2014 and 2013 is as follows:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Risk free Rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Volatility&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Share purchase warrants&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.85 to 2.78&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.13% to 0.78%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;199%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;1.22 to 3.53&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.25% to 1.10%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;0.00%&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;155.90% to 190.68%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets and liabilities measured&#13;at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability &amp;#150; warrants&#13;and Derivative liability &amp;#150; conversion option:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2014 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value Measurements &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,415&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of December 31, 2013&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Fair Value Measurements &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 36%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Carrying Value&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability - warrants&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;140,504&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Derivative liability &amp;#150; conversion option&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;582,300&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;722,804&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Financial assets&#13;and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative&#13;liability &amp;#150; warrants and Derivative liability &amp;#150; conversion option:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability - warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability - warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents changes in Level 3 liabilities&#13;measured at fair value for the year ended December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 34%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 40%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;&amp;#160;&amp;#160;Derivative liability &amp;#150; conversion option &lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 26%; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"&gt;Derivative liability &amp;#150; warrants&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; January 1, 2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$868,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$977,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Additions during the year&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;811,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;206,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total unrealized (gains) or losses included in net loss&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,096,000)&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,043,000)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; December 31, 2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$583,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$140,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Gain on settlement of debt&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(714,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of conversion option liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;131,000&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(131,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Balance &amp;#150; December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ 9,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following&#13;table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability &amp;#150; warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 89%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Additions during the quarter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,090,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(46,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; March 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="font-weight: normal"&gt;The&#13;following table summarizes the Company&amp;#146;s outstanding convertible note obligations:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-right: 1.8pt; text-align: right"&gt;&lt;b&gt;Stated&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;Principal Balance Outstanding&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;b&gt;Maturity Date&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: right"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;Rate&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: justify"&gt;&lt;b&gt;Conversion Terms&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;br /&gt;&#13;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 11%; padding-right: 0.8pt; text-align: justify"&gt;2/24/2011&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; padding-right: 0.8pt; text-align: justify"&gt;2/24/2014&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30%; padding-right: 0.8pt; text-align: justify"&gt;Variable at $25.00&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 0.8pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 0.8pt; text-align: right"&gt;$ 980,858&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/4/2011&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/4/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $25.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;215,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/6/2011&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/6/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $25.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;30,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;8/12/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/12/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;27,500&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;8/20/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;8/20/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;20,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;10/15/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;10/15/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $12.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;340,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/20/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/20/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10,748&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/18/2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/14/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;9.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $10.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;1/5/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/31/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $8.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;452,729&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;1/31/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/31/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $4.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;24,135&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;2/27/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;2/27/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;58,500&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/2/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/2/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;80,967&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/18/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/18/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;31,688&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/2/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/31/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $3.44&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/5/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;7/5/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;45,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/14/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/14/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $6.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;126,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/27/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/27/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;37,620&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/19/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/19/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $9.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;32,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;7/12/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;7/12/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;8.0&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Fixed at $3.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;96,800&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;10/18/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;4/18/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;Variable at $1.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;94,444&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;11/1/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;5/1/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $1.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;80,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;12/19/2013&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: justify"&gt;6/19/2014&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;None&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"&gt;Variable at $1.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt; text-align: right"&gt;277,222&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;12/23/2013&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;6/23/2014&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;10.0&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;Fixed at $7.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;536,400&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;Total convertible notes&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;3,697,611&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;Unamortized note discount&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;(535,634)&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="padding-right: 6.8pt; text-align: justify"&gt;&lt;b&gt;Total on Balance sheet&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: right"&gt;3,161,977&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&amp;#146;s stock&#13;options as of December 31, 2014 and 2013 and changes during the years is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Options&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2012&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;6.05&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;5.04&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2014 &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;65,430&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 18.8pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;4.04&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the status of the Company&amp;#146;s&#13;unvested options as of December 31, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 47%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Grant-Date&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Unvested, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;1,111&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Vested&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;(833)&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Cancelled&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Unvested, December 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 6.45pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.3pt; padding-left: 5.4pt; text-align: right"&gt;278&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 21.95pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;18.00&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ScheduleOfLongTermContractsForPurchaseOfElectricPowerTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&amp;#146;s share&#13;purchase warrants as of December 31, 2014 and changes during the year is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;149,452&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;25.85&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;2.76&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Issued&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,546,132&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;1.30&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;4.23&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Extinguished or expired&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(36,167)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;40.00&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Balance, December 31, 2014 &lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;2,659,417&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 20.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;1.83&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 23.5pt; padding-left: 5.4pt; text-align: right"&gt;4.15&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfLongTermContractsForPurchaseOfElectricPowerTextBlock>
    <us-gaap:ScheduleOfLongTermContractsForPurchaseOfElectricPowerTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of the&#13;Company&amp;#146;s share purchase warrants as of March 31, 2015 and changes during the period is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,659,417&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,090,975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Extinguished or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,742,892&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfLongTermContractsForPurchaseOfElectricPowerTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision (benefit) for&#13;the years ended December 31, 2014 and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 55%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 23%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 22%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Federal:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,265,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,321,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;State:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,265,000)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(1,321,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Change in valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;1,265,000&amp;#160; &lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,321,000&amp;#160; &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income tax provision (benefit)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effects of temporary differences that&#13;give rise to significant portions of the deferred tax assets as of December 31, 2014 and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 53%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 19%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Deferred tax assets:&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Ney operating loss carryforwards &lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;10,433,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;9,174,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Stock-based compensation&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,871,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$ &amp;#160;&amp;#160;&amp;#160;1,866,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Technology licensing fee&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;167,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;167,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Total deferred tax assets&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;12,471,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;11,207,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;(12,471,000)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(11,207,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <tpiv:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefit contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2014 and&#13;2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit)&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 27%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&#13;    &lt;td style="width: 21%; border-top: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;December 31, 2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;U.S. federal statutory rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;$&amp;#160;&amp;#160;&amp;#160;(10,449,000)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;(1,881,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Permanent differences&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- Non-cash loss on extinguishment of debt&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;9,122,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;893,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-Other permanent differences&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;62,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;(334,000)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;Change in valuation allowance&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 0.5in; text-align: right; text-indent: -0.25in"&gt;1,265,000&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1,322,000&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Income tax provision (benefit)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefit>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesAWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">1.50</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesBWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.40</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesCWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">1.00</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesDWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.75</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:InvestmentWarrantsExercisePrice contextRef="From2014-01-01to2014-12-31_custom_SeriesEWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">1.25</tpiv:InvestmentWarrantsExercisePrice>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesAWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesBWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P6M</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesCWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesDWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <tpiv:MaturityTermOfWarrants contextRef="From2014-01-01to2014-12-31_custom_SeriesEWarrantMember_custom_JanuaryTwelveTwoThousandFifteenMember">P5Y</tpiv:MaturityTermOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="Shares" decimals="INF">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="Shares" decimals="INF">7320000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USDPShares" decimals="INF">0.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="USD" decimals="0">950000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USD" decimals="0">1250000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="USD" decimals="0">50000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="USD" decimals="0">214000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents contextRef="From2014-01-01to2014-12-31_custom_MarchNineTwoThousandFifteenMember" unitRef="Pure" decimals="INF">0.025</tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents>
    <tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents contextRef="From2014-01-01to2014-12-31_custom_JanuaryTwelveTwoThousandFifteenMember" unitRef="Pure" decimals="INF">0.05</tpiv:PercentageOfNumberOfSharesOfCommonStockSoldInOfferingToPlacementAgents>
    <tpiv:NumberOfPostconsolidatedSharesOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">112000</tpiv:NumberOfPostconsolidatedSharesOfCommonStock>
    <tpiv:NumberOfPostconsolidatedSharesOfCommonStock contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">112000</tpiv:NumberOfPostconsolidatedSharesOfCommonStock>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">362000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">362000</us-gaap:LossContingencyDamagesPaidValue>
    <tpiv:BondPayment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">100000</tpiv:BondPayment>
    <tpiv:BondPayment contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">100000</tpiv:BondPayment>
    <tpiv:AmountPaidByConsultant contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">196204</tpiv:AmountPaidByConsultant>
    <tpiv:AmountPaidByConsultant contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">196204</tpiv:AmountPaidByConsultant>
    <tpiv:InterestPaidByConsultant contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.09</tpiv:InterestPaidByConsultant>
    <tpiv:InterestPaidByConsultant contextRef="From2015-01-01to2015-03-31" unitRef="Pure" decimals="INF">0.09</tpiv:InterestPaidByConsultant>
    <us-gaap:LegalFees contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">210255</us-gaap:LegalFees>
    <us-gaap:LegalFees contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">210255</us-gaap:LegalFees>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">196204</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">196204</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
    <tpiv:JudgmentAwardAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">51000</tpiv:JudgmentAwardAmount>
    <tpiv:JudgmentAwardAmount contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">51000</tpiv:JudgmentAwardAmount>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10449000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-1881000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">9122000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">893000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <tpiv:PermanentDifferencesotherPermanentDifferences contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">62000</tpiv:PermanentDifferencesotherPermanentDifferences>
    <tpiv:PermanentDifferencesotherPermanentDifferences contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-334000</tpiv:PermanentDifferencesotherPermanentDifferences>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">26982085</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">30686428</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">65430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">65430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">65430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">149452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2659417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">64742892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-01-01to2013-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2546132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">62090975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-36167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">25.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">40.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">50.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2015-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P2Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember">P4Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2013-01-01to2013-12-31">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P4Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember">P3Y11M16D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <tpiv:Exercised contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P0Y</tpiv:Exercised>
    <tpiv:ExtinguishedOrExpired contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P0Y</tpiv:ExtinguishedOrExpired>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31">P4Y15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2013-01-01to2013-12-31">P5Y15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P4Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember">P3Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="From2013-01-01to2013-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" xsi:nil="true" />
    <tpiv:Cancelledforfeited contextRef="From2014-01-01to2014-12-31">P0Y</tpiv:Cancelledforfeited>
    <tpiv:Cancelledforfeited contextRef="From2013-01-01to2013-12-31">P0Y</tpiv:Cancelledforfeited>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">1111</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">278</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">-833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">18.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" xsi:nil="true" />
    <tpiv:NumberOfOutstandingSharesOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">100</tpiv:NumberOfOutstandingSharesOfCommonStock>
    <tpiv:NumberOfOutstandingSharesOfCommonStock contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">5250</tpiv:NumberOfOutstandingSharesOfCommonStock>
    <tpiv:CommonStockAuthorizedFirst contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">150000000</tpiv:CommonStockAuthorizedFirst>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">100000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">94340</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">100000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Shares" decimals="INF">100000</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">1.06</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="USDPShares" decimals="INF">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">1.06</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2014-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember">P4Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">1.503</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Pure" decimals="INF">1.503</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Pure" decimals="INF">1.566</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.0163</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="Pure" decimals="INF">0.0166</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember_custom_MarchTwoThousandFourteenMember" unitRef="Pure" decimals="INF">0.014</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">700000</us-gaap:EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity>
    <us-gaap:PartnersCapitalAccountExchangesAndConversions contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">24900000</us-gaap:PartnersCapitalAccountExchangesAndConversions>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">31000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <tpiv:SharesOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">1400000</tpiv:SharesOfCommonStock>
    <us-gaap:MinorityInterestPreferredStockAmount contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">500000</us-gaap:MinorityInterestPreferredStockAmount>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">418000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleDebt contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4700000</us-gaap:ConvertibleDebt>
    <us-gaap:LicenseCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">91000</us-gaap:LicenseCosts>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">2724847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-03-31" unitRef="Shares" decimals="INF">330000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">64808000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">953642</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <tpiv:ConvertibleNotes contextRef="From2014-01-01to2014-12-31" unitRef="Shares" xsi:nil="true" />
    <tpiv:ConvertibleNotes contextRef="From2014-01-01to2014-03-31" unitRef="Shares" decimals="INF">15000</tpiv:ConvertibleNotes>
    <tpiv:ConvertibleNotes contextRef="From2015-01-01to2015-03-31" unitRef="Shares" xsi:nil="true" />
    <tpiv:ConvertibleNotes contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">738760</tpiv:ConvertibleNotes>
    <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">103284</tpiv:CommonStockWarrantsLiabilityTreatment>
    <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="From2014-01-01to2014-03-31" unitRef="Shares" decimals="INF">57000</tpiv:CommonStockWarrantsLiabilityTreatment>
    <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">12514000</tpiv:CommonStockWarrantsLiabilityTreatment>
    <tpiv:CommonStockWarrantsLiabilityTreatment contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">124284</tpiv:CommonStockWarrantsLiabilityTreatment>
    <tpiv:CommonStockWarrantsEquityTreatment contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">2556133</tpiv:CommonStockWarrantsEquityTreatment>
    <tpiv:CommonStockWarrantsEquityTreatment contextRef="From2014-01-01to2014-03-31" unitRef="Shares" decimals="INF">193000</tpiv:CommonStockWarrantsEquityTreatment>
    <tpiv:CommonStockWarrantsEquityTreatment contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">52229000</tpiv:CommonStockWarrantsEquityTreatment>
    <tpiv:CommonStockWarrantsEquityTreatment contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">25168</tpiv:CommonStockWarrantsEquityTreatment>
    <tpiv:CommonStockOptions contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">65430</tpiv:CommonStockOptions>
    <tpiv:CommonStockOptions contextRef="From2014-01-01to2014-03-31" unitRef="Shares" decimals="INF">65000</tpiv:CommonStockOptions>
    <tpiv:CommonStockOptions contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">65000</tpiv:CommonStockOptions>
    <tpiv:CommonStockOptions contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">65430</tpiv:CommonStockOptions>
    <tpiv:NumberOfOvarianCancerPatients contextRef="From2014-01-01to2014-12-31" unitRef="Patients" decimals="INF">30000</tpiv:NumberOfOvarianCancerPatients>
    <tpiv:PercentageOfBreastCancers contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.50</tpiv:PercentageOfBreastCancers>
    <tpiv:PercentageOfofOvarianCancers contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.95</tpiv:PercentageOfofOvarianCancers>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">5200</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">708000</tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion>
    <tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="0">708000</tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion>
    <tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion contextRef="From2015-01-01to2015-03-31" unitRef="USD" xsi:nil="true" />
    <tpiv:FairValueDerivativeLiabilityConversionOptionAtConversion contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">15000</tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions>
    <tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</tpiv:ExpensedPortionOfValueOfGrantedAndVestedOptions>
    <tpiv:FairValueOfSharePurchaseWarrants contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">14000</tpiv:FairValueOfSharePurchaseWarrants>
    <tpiv:FairValueOfSharePurchaseWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">303000</tpiv:FairValueOfSharePurchaseWarrants>
    <tpiv:FairValueOfSharePurchaseWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">111000</tpiv:FairValueOfSharePurchaseWarrants>
    <tpiv:ReceivedSubscriptionProceeds1 contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">1836000</tpiv:ReceivedSubscriptionProceeds1>
    <tpiv:ExcercisePriceOfWarrant contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">1.17</tpiv:ExcercisePriceOfWarrant>
    <tpiv:ExercisePriceOfPlacementShares contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">1.325</tpiv:ExercisePriceOfPlacementShares>
    <us-gaap:ProceedsFromFeesReceived contextRef="From2014-01-01to2014-12-31_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">265000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2014-01-01to2014-03-31" unitRef="USDPShares" decimals="INF">1.027</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2015-01-01to2015-03-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2014-04-01to2014-06-30" unitRef="USDPShares" decimals="INF">0.88</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2015-01-01to2015-03-31_custom_SharePurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">1.52</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="From2014-01-01to2014-03-31_custom_SharePurchaseWarrantsMember" unitRef="USDPShares" decimals="INF">5.84</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:NatureOfOperations contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 1:NATURE OF OPERATIONS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;TapImmune Inc.&#13;(the &amp;#147;Company&amp;#148;), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing&#13;in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious&#13;disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly&#13;stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation&#13;in tumor cells allowing their recognition and killing by the immune system.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A Phase I study&#13;at the Mayo Clinic is currently evaluating the safety and immune responses of a set of proprietary HER2/neu antigens that will&#13;be part of the &amp;#34;Prime&amp;#34; for a HER2/neu breast cancer vaccine.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A second Phase&#13;I trial is underway at Mayo Clinic (&amp;#147;Mayo&amp;#148;) in Ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha&#13;is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options&#13;are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively&#13;short for this type of cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately&#13;30,000 ovarian cancer patients newly diagnosed every year. These Folate Receptor Antigens are applicable to Ovarian and Triple&#13;Negative Breast Cancer. Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore&#13;the Company is hopeful that it might be an ideal candidate for orphan drug status in these indications.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Phase II advancement&#13;will be assessed in the second quarter of 2015. TapImmune has an exclusive option to license this set of peptides after successful&#13;phase 1 trials.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In addition, enhancing&#13;the visibility of cancer or infected cells to a patient&amp;#146;s immune system is a critical aspect of an effective vaccine. In&#13;this regard, TapImmune&amp;#146;s PolyStart&amp;#153; nucleic acid-based technology provides a four-fold increase in target cell specific&#13;naturally processed antigenic epitopes on a cells surface. This increased cell surface presentation corresponding increases activated&#13;Helper and/or long-lived Killer T-cell populations that then effectively seek out and work to destroy a patient&amp;#146;s cancer&#13;cells.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;The&#13;Company is also exploiting the emerging field of vaccinomics for the development of vaccines applicable to a broad patient population.&#13;TapImmune's immunotherapy technologies are also aimed at the prevention of emerging viral pathogens for pandemics and biodefense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;These consolidated&#13;financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction&#13;of liabilities in the normal course of business. As at December 31, 2014, the Company had a working capital deficiency and has&#13;incurred significant losses since inception in the development of its business. Further losses are anticipated raising substantial&#13;doubt as to the Company&amp;#146;s ability to continue as a going concern. The ability of the Company to continue as a going concern&#13;is dependent on raising additional capital to fund clinical trials, ongoing research and development, maintenance and protection&#13;of patents, accommodation from certain debt obligations and ultimately on generating future profitable operations. Planned expenditures&#13;relating to current and future clinical trials of the Company&amp;#146;s immunotherapy vaccine will require significant additional&#13;funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements.&#13;The Company&amp;#146;s future capital requirements will depend on many factors including the rate and extent of scientific progress&#13;in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals,&#13;pursuing further patent protections and the timing and costs of commercialization activities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Management is&#13;addressing going concern remediation through seeking new sources of capital, restructuring and retiring debt through conversion&#13;to equity and debt settlement arrangements with creditors, cost reduction programs and seeking possible joint venture participation.&#13;Management&amp;#146;s plans are intended to return the Company to financial stability and improve continuing operations. The Company&#13;is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet&#13;immediate working capital requirements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Historically the&#13;Company has raised capital through issuances of various financial instruments and the Company recently completed significant restructuring&#13;of outstanding debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical&#13;work and to progress clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product&#13;development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern&#13;uncertainties for the Company over the next twelve months.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;There is no certainty&#13;that the Company will be able to arrange sufficient funding to satisfy current debt obligations or to continue development of products&#13;to marketability.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NatureOfOperations contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 1:&amp;#160; NATURE OF OPERATIONS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;TapImmune Inc.&#13;(the &amp;#147;Company&amp;#148;), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing&#13;in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and&amp;#160;&#13;infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach&#13;broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen&#13;presentation in tumor cells allowing their recognition and killing by the immune system.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 2:SUMMARY&#13;OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;These financial&#13;statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted&#13;in the United States of America (&amp;#147;GAAP&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Principles&#13;of Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;These financial&#13;statements include the accounts of the Company and its wholly-owned subsidiaries GeneMax Pharmaceuticals Inc. (&amp;#147;GPI&amp;#148;)&#13;and GeneMax Pharmaceuticals Canada Inc. (&amp;#147;GPC&amp;#148;). All significant intercompany balances and transactions are eliminated&#13;upon consolidation. In the fourth quarter of fiscal 2014, the Company dissolved GPC and no longer has any Canadian subsidiary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Preparation of&#13;the Company&amp;#146;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect&#13;certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant&#13;areas requiring management&amp;#146;s estimates and assumptions include deferred taxes and related tax balances and disclosures, determining&#13;the fair value of stock-based compensation and stock based transactions, the fair value of the components of the convertible notes&#13;payable and accrued liabilities. Matters impacting the Company&amp;#146;s ability to continue as a going concern and contingencies&#13;also involve the use of estimates and assumptions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Fair Value&#13;Measurements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value&#13;of certain of the Company&amp;#146;s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued&#13;liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial&#13;assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information&#13;used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of&#13;the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66px; text-align: justify; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66px; text-align: justify; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66px; text-align: justify; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#149;&amp;#160;&amp;#160;&amp;#160;Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial Instruments and Concentration of Credit Risk.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair values&#13;of cash, accounts payable, and other current monetary liabilities approximate their carrying values due to the immediate or short-term&#13;maturity of these financial instruments. The Company&amp;#146;s operations and financing activities are conducted primarily in United&#13;States dollars, and as a result the Company is not subject to significant exposure to market risks from changes in foreign currency&#13;rates. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks&#13;arising from assets and liabilities classified as financial instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Prior Period&#13;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Certain prior&#13;period amounts that were combined in the December 31, 2013 consolidated financial statements have been reclassified for comparability&#13;with the December 31, 2014 presentation. These reclassifications had no effect on previously reported net loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Stock-Based&#13;Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Stock-based compensation&#13;is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to&#13;vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&#13;The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate.&#13;The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ&#13;from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&amp;#160;&amp;#151;&#13;The expected term of options represents the period that the Company&amp;#146;s stock-based awards are expected to be outstanding based&#13;on the simplified method, which is the half-life from vesting to the end of its contractual term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Risk-Free Interest&#13;Rate&lt;/i&gt;&amp;#160;&amp;#151; The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon&#13;issues with an equivalent remaining term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Expected Dividend&lt;/i&gt;&amp;#160;&amp;#151;&#13;The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable&#13;future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock&#13;options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Deferred Financing&#13;Costs&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company defers&#13;direct costs incurred in connection with the sale of common shares which are offset against the proceeds of the financing upon&#13;completion. Costs incurred in connection with convertible loans payable are deferred and amortized as a financing cost over the&#13;term of the convertible loans. Upon conversion of the loan, any unamortized amount of deferred financing costs will be charged&#13;to stockholders&amp;#146; equity as a cost of financing.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Research and&#13;Development Costs&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;acquired development and marketing rights to certain technologies. The rights and licenses acquired are considered rights to unproven&#13;technology which may not have alternate future uses and therefore, have been expensed as incurred as research and development costs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company follows&#13;the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized&#13;for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities&#13;and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected&#13;to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential&#13;deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of allowances&#13;against deferred tax assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Derivative&#13;Liability&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company evaluates&#13;its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts&#13;qualify as derivatives to be separately accounted for in accordance with ASC 810-10-05-4 and&amp;#160;&amp;#160;815-40. This accounting&#13;treatment requires that the carrying amount of embedded derivatives be marked-to-market at each balance sheet date and carried&#13;at fair value. In the event that the fair value is recorded as a liability, the change in fair value during the period is recorded&#13;in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative&#13;instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In circumstances&#13;where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded&#13;derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments&#13;are accounted for as a single, compound derivative instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The classification&#13;of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at&#13;the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification&#13;are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities&#13;will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative&#13;instrument is expected within 12 months of the balance sheet date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In evaluating&#13;the application of ASC 815-40, management must determine whether an instrument (or an embedded feature) is indexed to the Company&amp;#146;s&#13;own stock. ASC 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial&#13;instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&amp;#146;s contingent exercise and&#13;settlement provisions. The application of ASC 815-40-15 has affected the accounting for (i) certain freestanding warrants that&#13;contain exercise price adjustment features and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii)&#13;certain free standing warrants that contain contingently puttable cash settlement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;evaluated the application ASC 480-10&amp;#160;&lt;i&gt;Distinguishing liabilities from equity&lt;/i&gt;, ASC 815-40&amp;#160;&lt;i&gt;Contracts in an Entity&amp;#146;s&#13;Own Equity&lt;/i&gt;&amp;#160;and ASC 718-10&amp;#160;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt;&amp;#160;to the issued and outstanding warrants&#13;to purchase common stock that were issued with the convertible notes, private placements, consulting agreements, and various debt&#13;settlements during 2009 through 2012. Based on the guidance, management concluded these instruments are required to be accounted&#13;for as derivatives either due to a ratchet down protection feature available on the exercise price (Note 5) or a holder&amp;#146;s&#13;right to put the warrants back to the Company for cash under certain conditions or a conversion option feature with conversion&#13;into variable number of shares. Under ASC 815-40-25, the Company records the fair value of these warrants and conversion options&#13;(derivatives) on its balance sheet, at fair value, with changes in the values reflected in the Statements of Operations as &amp;#147;Changes&#13;in fair value of derivative liabilities&amp;#148;. The fair value of the share purchase warrants are recorded on the Balance Sheet&#13;under &amp;#145;Derivative liability &amp;#150; warrants&amp;#146; and the fair value of the conversion options are recorded on the Balance&#13;Sheet under &amp;#145;Derivative liability &amp;#150; conversion option&amp;#146;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Loss per Common&#13;Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Basic loss per&#13;share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding&#13;for the period. If applicable, diluted earnings per share reflect the potential dilution of securities that could share in the&#13;earnings (loss) of the Company. The common shares potentially issuable on conversion of outstanding convertible debentures, warrants&#13;and stock options are anti-dilutive and have not been included in the calculation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Net Loss per&#13;Share Applicable to Common Stockholders&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Options, warrants,&#13;and convertible debt outstanding were all considered anti-dilutive for the years ended December 31, 2014 and 2013, due to net losses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following&#13;securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods&#13;presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;65,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;65,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock warrants - equity treatment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,556,133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,168&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock warrants - liability treatment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;103,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;124,284&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;738,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Excluded potentially dilutive securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,724,847&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;953,642&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Accounting Standards&#13;Update No. 2014-10,&amp;#160;&lt;i&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including&#13;an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&lt;/i&gt;&amp;#160;removes all incremental financial reporting&#13;requirements for development stage entities, including the removal of reporting of the cumulative results of operations and cash&#13;flows for the period from inception to the end of the current period. The update is effective for the first annual period beginning&#13;after December 15, 2014. Early adoption is permitted, and the Company has adopted this change effective with its form 10-Q filing&#13;for the period ending September 30, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;Accounting&#13;Standard Update No. ASU 2014-15, Presentation of Financial Statements&amp;#151;Going Concern (Subtopic 205-40): Disclosure of Uncertainties&#13;about an Entity&amp;#146;s Ability to Continue as a Going Concern. The amendments in this update are effective for the annual period&#13;ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company&#13;is currently evaluating the impact of this update on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 4:&amp;#160;&#13;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;There have been&#13;no material changes in the Company&amp;#146;s significant accounting policies to those previously disclosed in the Company&amp;#146;s&#13;annual report on Form 10-K, which was filed with the SEC on April 15, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Prior Period&#13;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Certain prior&#13;period amounts that were combined in the March 31, 2014 consolidated financial statements have been reclassified for comparability&#13;with the March 31, 2015 presentation. These reclassifications had no effect on previously reported net loss.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 3:ACCOUNTS&#13;PAYABLE AND ACCRUED LIABILITIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Accounts Payable and Accrued Liabilities&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Trade accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;620,826&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,450,083&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Share-settled debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,348,663&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Accrued liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68,448&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;201,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Employee payroll and severance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;220,290&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;Accrued interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,088&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;558,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;693,362&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,778,401&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During fiscal&#13;2014 the Company converted $2,415,000 accounts payable and accrued liabilities into 1,836,000 shares of common stock. The fair&#13;value of the shares, based on the trading price of the stock on the date of conversion, was $4,349,000 and the Company recorded&#13;a loss on extinguishment of $1,934,000.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 4:RESEARCH&#13;AGREEMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Crucell Holland&#13;B.V. (&amp;#147;Crucell&amp;#148;) &amp;#150; Research License and Option Agreement&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Effective August&#13;7, 2003, Crucell and the Company&amp;#146;s subsidiary GPI entered into a five-year research license and option agreement. In addition,&#13;retroactively effective August 7, 2008, the Company negotiated an amended license agreement for the use of Crucell&amp;#146;s adenovirus&#13;technology. The Company was required to make annual license payments on the anniversary of the effective date for the three year&#13;term equal to $91,000 per annum for three years through December 2011. As of December 31, 2013 and 2014, the Company accrued $492,365&#13;under the amended agreement, inclusive of 15% interest on outstanding amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;not made use of the Crucell technology in its current work and has not asked for nor received any work product. Management hopes&#13;to settle the outstanding amounts with Crucell in 2015 and formally terminate the research license.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 5:DERIVATIVE&#13;LIABILITY&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During 2014 the&#13;Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with&#13;the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the&#13;Statement of Operations. The inputs utilized in the final mark to market were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter ending June 30, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Strike price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility (annual)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;199.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;199.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value of Conversion Option at extinguishment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;708,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;712,000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of quantitative&#13;information with respect to valuation methodology and significant unobservable inputs used for the Company&amp;#146;s common stock&#13;purchase warrants that are categorized within Level 3 of the fair value hierarchy for the years ended 2014 and 2013 is as follows:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 23%; border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2.25pt double"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2.25pt double"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Contractual&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk free Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 9%; border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Share purchase warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.85 to 2.78&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.13% to 0.78%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;199%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.22 to 3.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.25% to 1.10%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;155.90% to 190.68%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The foregoing&#13;assumptions are recalculated every reporting period and are subject to change based primarily on management&amp;#146;s assessment&#13;of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Financial Assets&#13;and Liabilities Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Financial assets&#13;and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative&#13;liability &amp;#150; warrants and Derivative liability &amp;#150; conversion option:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability - warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,415&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Carrying Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability - warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;140,504&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;140,504&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;140,504&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability &amp;#150; conversion option&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;582,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;582,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;582,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;722,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;722,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;722,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;There were no transfers between Level&#13;1, 2 or 3 during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;The following&#13;table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability &amp;#150; conversion option&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability &amp;#150; warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; January 1, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;868,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;977,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Additions during the year&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;811,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;206,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total unrealized (gains) or losses included in net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,096,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,043,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;583,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;140,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gain on settlement of debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(714,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value of conversion option liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(131,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The valuation&#13;of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock,&#13;the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the&#13;warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately&#13;incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability&#13;on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants&#13;are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes&#13;in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements&#13;of Operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The net cash settlement&#13;value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the&#13;value of the following inputs at that time: the consideration value per share of the Company&amp;#146;s common stock, the volatility&#13;of the Company&amp;#146;s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based&#13;on U.S. Treasury security yields, and the Company&amp;#146;s dividend yield. The warrant requires use of a volatility assumption equal&#13;to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement&#13;of a Fundamental Transaction.&lt;/p&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 6:&amp;#160; DERIVATIVE LIABILITY&#13;- WARRANTS AND DERIVATIVE LIABILITY &amp;#150; CONVERSION OPTION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of quantitative&#13;information with respect to valuation methodology and significant unobservable inputs used for the Company&amp;#146;s common stock&#13;purchase warrants that are categorized within Level 3 of the fair value hierarchy for the three months ended 2015 and 2014 is as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Share Purchase Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Strike price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.84&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility (annual)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;155.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;159.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The foregoing&#13;assumptions are reviewed quarterly and are subject to change based primarily on management&amp;#146;s assessment of the probability&#13;of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Financial Assets&#13;and Liabilities Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Financial assets&#13;and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative&#13;liability &amp;#150; warrants and Derivative liability &amp;#150; conversion option:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability - warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="18" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability - warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;There were no&#13;transfers between Level 1, 2 or 3 during the three months ended March 31, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following&#13;table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2015:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative liability &amp;#150; warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 89%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Additions during the quarter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,090,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in fair value of warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(46,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance &amp;#150; March 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,053,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The valuation&#13;of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock,&#13;the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the&#13;warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately&#13;incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability&#13;on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants&#13;are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes&#13;in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements&#13;of Operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During 2014 the&#13;Company entered into numerous extinguishment agreements with various holders. As a result the derivative liability associated with&#13;the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the&#13;Statement of Operations. The inputs utilized in the final mark to market were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Conversion Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield (per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Strike price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility (annual)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;199.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual term (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value of Conversion Option at extinguishment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;708,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:MortgageNotesPayableDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 6:CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;The following table summarizes the&#13;Company&amp;#146;s outstanding convertible note obligations:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stated&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Principal Balance Outstanding&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;b&gt;Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Conversion Terms&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 12%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/24/2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/24/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $25.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 6%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 7%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$ 980,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/4/2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/4/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $25.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;215,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/6/2011&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/6/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $25.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8/12/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/12/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;27,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8/20/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8/20/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10/15/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10/15/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;340,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/20/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/20/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/18/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/14/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $10.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1/5/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/31/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $8.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;452,729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1/31/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/31/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $4.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;24,135&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/27/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/27/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/2/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/2/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,967&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/18/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/18/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,688&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/2/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/31/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $3.44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/5/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/5/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/14/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/14/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $6.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;126,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/27/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/27/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37,620&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/19/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/19/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $9.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/12/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/12/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;96,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10/18/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/18/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;94,444&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11/1/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5/1/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;80,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/19/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/19/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;None&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Variable at $1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;277,222&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12/23/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6/23/2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed at $7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;536,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total convertible notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,697,611&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unamortized note discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(535,634)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total on Balance sheet&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,161,977&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Issuance of&#13;Convertible Preferred Stock&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;the Company issued $418,000 of convertible notes.&amp;#160;&amp;#160;The notes carried no interest rate and were converted shortly thereafter&#13;(see Extinguishment loss) into preferred stock and immediately into common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Debt converted&#13;to Preferred Stock and immediately converted into common stock&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0"&gt;During the year, note holders that included Convertible notes, Loans payable, Promissory notes-related&#13;party &amp;#38; Due to related party exchanged approximately $4.7 million of debt and $0.5 million of accrued interest for shares of&#13;preferred stock, which was immediately converted into 14.0 million shares of common stock with a fair value of approximately $31&#13;million. The total loss on extinguishment associated with the note conversions was $24.9 million, which includes the extinguishment&#13;of the derivative liability &amp;#150; conversion option of $0.7 million.&lt;/p&gt;</us-gaap:MortgageNotesPayableDisclosureTextBlock>
    <tpiv:LoansPayableDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 7:LOANS&#13;PAYABLE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As at December&#13;31, 2014, there were unsecured loan payable in the amount of $nil (December 31, 2013 - $42,200). During the year ended December&#13;31, 2014, investors converted $37,000 and a related party converted $5,200 of the loan into preferred stock which was immediately&#13;converted into common stock (see note 6).&lt;/p&gt;</tpiv:LoansPayableDisclosureTextBlock>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 8:PROMISSORY&#13;NOTES, RELATED PARTY&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;outstanding promissory notes in the amount of $52,942 (December 31, 2013 - $277,942), of which $23,000 of promissory notes are&#13;from an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;ended December 31, 2014, a note holder converted outstanding principal of $210,000 and accrued interest of $12,000 into preferred&#13;stock which was immediately converted into common shares (see note 6).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;ended December 31, 2014, $15,000 (2013 - $nil) of the promissory notes were repaid to an officer and director of the Company.&lt;/p&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 7:&amp;#160; PROMISSORY NOTES,&#13;RELATED PARTY&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes are from&#13;an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.&lt;/p&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 9:DUE&#13;TO RELATED PARTIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;ended December 31, 2014 the Company has outstanding promissory notes in the amount of $nil (December 31, 2013 - $369,000). During&#13;the fiscal year 2014, the related parties converted the notes of $369,000 into preferred stock which was immediately converted&#13;into common stock (See note 6).&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 10:&lt;/b&gt;&amp;#160;&amp;#160;&lt;b&gt;CAPITAL&#13;STOCK&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Stock Split&#13;and increase in authorized shares&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On February 18,&#13;2014, the Company completed a reverse stock split thereby issuing 1 new share for each 100 outstanding shares of the Company&amp;#146;s&#13;common stock and amended the Company&amp;#146;s Articles of Incorporation to increase the authorized shares of common stock from 150,000,000&#13;shares of common stock to 500,000,000 shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Share Capital&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On January 6,&#13;2014, the Company designated 1,250,000 Series A preferred shares par value $0.001 (&amp;#147;Series A Convertible Preferred Stock&amp;#148;).&#13;Each share of Series A Convertible Preferred Stock automatically converted into five (5) shares of the Company&amp;#146;s common stock&#13;upon the occurrence of the 1:100 reverse stock split.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On February 18,&#13;2014, the Company created a class of up to 1,500,000 preferred shares, par value $0.001, called Series B convertible preferred&#13;stock (&amp;#147;Series B Convertible Preferred Stock&amp;#148;). The terms of the Series B Convertible Preferred Stock are:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;rank pari passu to the common stock with respect to rights on liquidation, winding up and dissolution;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;have no dividend rights except as may be declared by the Board in its sole and absolute discretion;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;shall have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation&amp;#146;s common stock; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;shall automatically convert into seven (7) shares of common upon the occurrence of a 1:100 reverse stock split.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;All prior period&#13;share transactions included in the Company&amp;#146;s stock transactions and balances have been retroactively restated for the reverse&#13;stock splits described above. There are no shares outstanding under preferred shares as of December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;2014 Share&#13;Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Consulting&#13;services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;ended December 31, 2014, the Company issued in aggregate 811,000 shares of common stock in exchange for consulting services for&#13;which performance was complete. The fair value of the common stock recognized was approximately $954,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Private placements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;ended December 31, 2014, the Company entered into a Securities Purchase Agreement with a single institutional investor for the&#13;sale of 1,886,792 units at a purchase price of $1.06 per unit, for a total purchase price of $1,836,000, net of finders&amp;#146;&#13;fee of $164,000. Each unit consists of one common share and one share purchase warrant exercisable at $1.17 for a period of 5 years.&#13;The Company also issued 94,340 placement agent share purchase warrants to acquire an equivalent number of common shares of the&#13;Company, at an exercise price of $1.325 per share for an exercise period of up to five years from the issuance date. The warrants&#13;were included within equity. The fair value of these warrants was determined to be $111,000, using the Black-Scholes Option Pricing&#13;Model with a contractual term of 5 years, a risk free interest rate of 1.66%, a dividend yield of 0%, and an expected volatility&#13;of 150.3%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year&#13;ended December 31, 2014, the Company received subscription proceeds of $265,000 for 265,000 units. Each unit consists of one share&#13;of common stock and one share purchase warrant exercisable at $2.50 for a period of 3 years. The Company also issued 5,250 shares&#13;of common stock as finders&amp;#146; fee relating to the subscription proceeds. The fair value of the common stock was determined&#13;to be $5,250.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Stock Compensation&#13;Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On October 14,&#13;2009, the Company adopted the 2009 Stock Incentive Plan (the &amp;#147;2009 Plan&amp;#148;) which supersedes and replaces the 2007 Stock&#13;Plan. The 2009 Plan allows for the issuance of up to 100,000 common shares. Options granted under the Plan shall be at prices and&#13;for terms as determined by the Board of Directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The expensed portion&#13;of the value of the granted and vested options during the year ended December 31, 2014 was $15,000 (2013 - $132,093) which was&#13;recorded as stock based consulting and management fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Share purchase&#13;options&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of the&#13;Company&amp;#146;s stock options as of December 31, 2014 and 2013 and changes during the years is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Options&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;65,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;65,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Cancelled/Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;65,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;At December 31, 2014, the intrinsic&#13;value of the vested options was equal to $nil (2013 - $nil).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;A summary of the status of the Company&amp;#146;s&#13;unvested options as of December 31, 2014 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Grant-Date&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Unvested, December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,111&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(833&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Unvested, December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Share Purchase Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In September,&#13;2014, the Company issued 100,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an&#13;exercise price of $1.15 per share for an exercise period of up to five years from the issuance date. The warrants were issued pursuant&#13;to a service agreement. The fair value of these warrants was determined to be $105,000, using the Black-Scholes Option Pricing&#13;Model with a contractual term of 5 years, a risk free interest rate of 1.63%, a dividend yield of 0%, and an annual volatility&#13;of 150.18%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In March, 2014,&#13;the Company issued 100,000 share purchase warrants to acquire an equivalent number of common shares of the Company, at an exercise&#13;price of $4.00 per share for an exercise period of up to four years from the issuance date. The warrants were issued pursuant to&#13;a technology option agreement. The fair value of these warrants was determined to be $303,000 and was recorded in general and administrative&#13;expenses. The weighted average assumptions used for the Black-Scholes option-pricing model to value these warrants were: volatility&#13;of 156.6%, risk free rate of 1.4%, term of 4 years and dividend rate of 0%. The Company used the Black-Scholes option-pricing model&#13;as the resultant fair value is not significantly different than the Monte Carlo option pricing model. In August 2014, the Company&#13;repriced the 100,000 warrants by reducing the exercise price from $4.00 to $1.06. As a result, the Company recorded incremental&#13;fair value of $14,000 during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of the&#13;Company&amp;#146;s share purchase warrants as of December 31, 2014 and changes during the year is presented below:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;149,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,546,132&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Extinguished or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(36,167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,659,417&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 8:&amp;#160;&#13;CAPITAL STOCK&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;2015 Share&#13;Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Private placements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In January, 2015,&#13;the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price&#13;of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders&amp;#146; fee and offering expenses of approximately&#13;$214,000. Each unit consisting of (i) one share of the Company&amp;#146;s Common Stock, (ii) one Series A warrant to purchase one&#13;share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one&#13;share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase&#13;one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the &amp;#147;January 2015&#13;Warrants&amp;#148;). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable&#13;at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series&#13;D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year&#13;term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and&#13;to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Pursuant to a&#13;placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms&#13;as the January 2015 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Series A warrants&#13;were issued with price reset features. The fair value of these warrants was determined to be $1,346,000 and recognized as a derivative&#13;liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value&#13;of Series B, C, D &amp;#38; E warrants was determined to be $4,635,000 and was included within equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In March, 2015,&#13;the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a&#13;purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders&amp;#146; fee and offering&#13;expenses of approximately $50,000. Each unit consisting of (i) one share of the Company&amp;#146;s Common Stock, (ii) one Series A&#13;warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series&#13;C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series&#13;E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby&amp;#160;&amp;#160;collectively referred&#13;to as the &amp;#147;March 2015 Warrants&amp;#148;). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Pursuant to a&#13;placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms&#13;as the March 2015 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Series A warrants&#13;were issued with price reset features. The fair value of these warrants was determined to be $744,000 and recognized as a derivative&#13;liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The fair value&#13;of Series B, C, D &amp;#38; E warrants was determined to be $2,588,000 and was included within equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Share Purchase&#13;Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of the&#13;Company&amp;#146;s share purchase warrants as of March 31, 2015 and changes during the period is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Weighted Average&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,659,417&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,090,975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.96&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Extinguished or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Balance, March 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,742,892&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 11:&amp;#160;&amp;#160;INCOME TAXES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;The income tax provision (benefit)&#13;for the years ended December 31, 2014 and 2013 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,265,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,321,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Deferred&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,265,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,321,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,265,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,321,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The effects of&#13;temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2014 and 2013 are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Ney operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,433,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,174,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,871,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,866,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Technology licensing fee&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;167,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;167,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,471,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,207,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(12,471,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(11,207,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred tax assets, net of valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company assesses&#13;the likelihood that deferred tax assets will be realized.&amp;#160;&amp;#160;To the extent that realization is not likely, a valuation&#13;allowance is established.&amp;#160;&amp;#160;Based upon the history of losses, management believes that it is more likely than not that&#13;future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended&#13;December 31, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;not filed U.S tax returns since inception, but is in the process of filing tax returns for the years ended December 31, 2014, 2013,&#13;2012, 2011, 2010, and 2009. The Net operating losses (&amp;#147;NOLs&amp;#148;) will not be available to reduce future taxable income&#13;until the returns are filed. Assuming these returns are filed, as of December 31, 2014 and 2013, the Company has approximately&#13;$30,686,428 and $26,982,085, respectively, of federal NOLs that may be available to offset future taxable income, if any.&amp;#160;&amp;#160;The&#13;federal net operating loss carryforwards, if not utilized, will expire beginning in 2023.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company has&#13;also not filed any Canadian tax returns for GPC, which was dissolved in the fourth quarter of fiscal year 2014. The Company could&#13;be subject to fines and penalties for not filing the tax returns. The Company does not know the quantum of such fines and penalties,&#13;if any, and no liabilities have been accrued in the fiscal year 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In accordance&#13;with Section 382 of the Internal Revenue code, the usage of the Company&amp;#146;s net operating loss carryforwards may be limited&#13;in the event of a change in ownership.&amp;#160;&amp;#160;A full Section 382 analysis has not been prepared and NOLs could be subject to&#13;limitation under Section 382.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the years&#13;ended December 31, 2014 and 2013, the expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with&#13;the actual tax provision (benefit) as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="border-top: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;U.S. federal statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,449,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,881,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;- Non-cash loss on extinguishment of debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,122,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;893,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-Other permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;62,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(334,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,265,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,322,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;ASC 740 prescribes&#13;a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken&#13;or expected to be taken in a tax return.&amp;#160;&amp;#160;For those benefits to be recognized, a tax position must be more-likely-than-not&#13;to be sustained upon examination by taxing authorities.&amp;#160;&amp;#160;As of December 31, 2014 and 2013, there were no unrecognized&#13;tax benefits.&amp;#160;&amp;#160;The Company recognizes accrued interest and penalties as income tax expense.&amp;#160;&amp;#160;No amounts were&#13;accrued for the payment of interest and penalties at December 31, 2014 and 2013.&amp;#160;&amp;#160;The Company is currently not aware&#13;of any issues under review that could result in significant payments, accruals or material deviation from its position in the next&#13;year.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 12:CONTINGENCIES&#13;AND COMMITMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Contingencies:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Consultant&#13;Litigation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In May 2012, the&#13;Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity of the services&#13;provided and initially were able to delay the sale of the contested shares. The Company was not successful in recovering the contested&#13;shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as a result of the contesting&#13;of the issuance of the shares has been filed in the Supreme Court of New York. The claim is for damages on the difference between&#13;market price at the time the Company was able to delay the sale of his shares and the market price at the time of the sale of all&#13;of his shares. As the result of a judicial decision in New York the consultant received a bond payment of approximately $100,000&#13;that the Company had used to secure a temporary restraining order against the issuance of stock to him. Following hearings at the&#13;International Arbitration Tribunal held in New York on&amp;#160;May 13-16&amp;#160;the arbitrator ordered (on July 18, 2014) the consultant&#13;to pay TapImmune $196,204 plus 9% interest from the date of the award.&amp;#160;&lt;font style="background-color: white"&gt;The Company is&#13;attempting to collect the award from Mr. Gardner.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The law firm that&#13;we used to pursue the Gardner Action was awarded a judgment against us for $210,255 of unpaid legal fees (&amp;#147;G&amp;#38;S Judgment&amp;#148;).&#13;Shareholders of the Company acquired the G&amp;#38;S Judgment in full, converted that Judgment into preferred shares of the Company&#13;(which in turn converted into common stock) and subsequently released the Company from any liability related thereto.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On July 18, 2014,&#13;the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the matter of TapImmune&#13;Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This award stemmed from&#13;the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found that we were fraudulently&#13;induced into entering said agreement through &amp;#147;1) misrepresentations as to what he would or could do for the Company, including&#13;raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining financing for TapImmune&amp;#148;&#13;among other reasons. We are attempting to collect the award from Mr. Gardner.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;One of our suppliers,&#13;Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them. We intend on settling&#13;that matter in the second quarter of 2015.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 9:&amp;#160; CONTINGENCIES AND&#13;COMMITMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Contingencies:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Consultant Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In May 2012, the&#13;Company issued 112,000 post-consolidated shares of common stock to two consultants. The Company contested the validity of the services&#13;provided and initially was able to delay the sale of the contested shares. The Company was not successful in recovering the contested&#13;shares. A claim for alleged damages of approximately $362,000 plus costs by one of the consultants as a result of the contesting&#13;of the issuance of the shares was filed in the Supreme Court of New York. The claim was for damages on the difference between market&#13;price at the time the Company was able to delay the sale of his shares and the market price at the time of the sale of all of his&#13;shares. As the result of a judicial decision in New York the consultant received a bond payment of approximately $100,000 that&#13;the Company had used to secure a temporary restraining order against the issuance of stock to him. Following hearings at the International&#13;Arbitration Tribunal held in New York on&amp;#160;May 13-16, 2014&amp;#160;the arbitrator ordered (on July 18, 2014) the consultant to&#13;pay TapImmune $196,204 plus 9% interest from the date of the award.&amp;#160;&lt;font style="background-color: white"&gt;The Company is attempting&#13;to collect the award from Mr. Michael Gardner.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On July 18, 2014,&#13;the International Center for Dispute Resolution International Arbitration Tribunal issued a Final Award in the matter of&amp;#160;&amp;#160;TapImmune&#13;Inc. vs. Michael Gardner awarding TapImmune $196,204 plus post-award interest at a rate of 9% per year. This award stemmed from&#13;the dispute discussed above with Mr. Gardner regarding the May 2012 consulting agreement. The arbitrator found that we were fraudulently&#13;induced into entering said agreement through &amp;#147;1) misrepresentations as to what he would or could do for the Company, including&#13;raising funds, and 2) omissions about his reputation and ability to obtain or assist in obtaining financing for TapImmune&amp;#148;&#13;among other reasons. We are attempting to collect the award from Mr. Gardner.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Vendor Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;One of our suppliers,&#13;Fischer Scientific was awarded a judgment against us for $51,000 which is equal to the amount owed to them and is currently accrued&#13;on the balance sheet. We intend on settling that matter in the second quarter of 2015.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 13:SUBSEQUENT&#13;EVENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On January 12, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders&amp;#146; fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company&amp;#146;s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants collectively, the &amp;#147;January 2015 Warrants&amp;#148;). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Pursuant to a&#13;placement agent agreement, the Company agreed to issue warrants to purchase an aggregate of up to 5% of the aggregate number of&#13;shares of common stock sold in the offering to the placement agents. The placement agent warrants have substantially the same terms&#13;as the January 2015 Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On March 9, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders&amp;#146; fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company&amp;#146;s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants collectively, the &amp;#147;March 2015 Warrants&amp;#148;). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Pursuant to a&#13;placement agent agreement, the Company agreed to issue warrants to purchase an aggregate of up to 2.5% of the aggregate number&#13;of shares of common stock sold in the offering to the placement agents. The placement agent warrants have substantially the same&#13;terms as the March 2015 Warrants.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 2: &amp;#160;BASIS&#13;OF PRESENTATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The accompanying&#13;unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in&#13;the United States of America (&amp;#147;U.S. GAAP&amp;#148;) for interim financial information and pursuant to the instructions to Form&#13;10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (&amp;#147;SEC&amp;#148;) and on the same basis as the&#13;Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31,&#13;2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments,&#13;which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the&#13;periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;The&#13;results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31,&#13;2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial&#13;statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements.&#13;The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the&#13;year ended December 31, 2014, and notes thereto included in the Company&amp;#146;s annual report on Form 10-K.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 3: &amp;#160;LIQUIDITY&#13;AND FINANCIAL CONDITION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company&amp;#146;s&#13;activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing&#13;research and development. Successful completion of the Company&amp;#146;s development programs and, ultimately, the attainment of&#13;profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure&#13;financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception,&#13;the Company has been funded by a combination of equity and debt financings.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company expects&#13;to continue to incur substantial losses over the next several years during its development phase. To fully execute its business&#13;plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company&amp;#146;s&#13;product candidates will require regulatory approval prior to commercialization. These activities may span many years and require&#13;substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely&#13;impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities&#13;and, in the longer term, revenue from product sales.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As of March 31,&#13;2015, the Company had cash and cash equivalents of approximately $1,454,000. Historically, the Company has net losses and negative&#13;cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management&#13;intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management&#13;plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or&#13;strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable&#13;terms, or at all. These matters raise substantial doubt about the Company&amp;#146;s ability to continue as a going concern. The financial&#13;statements do not include any adjustments that might result from the outcome of these uncertainties.&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <tpiv:PotentiallyDilutiveSecuritiesTextBlock contextRef="From2015-01-01to2015-03-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"&gt;&lt;font style="text-transform: uppercase"&gt;Note&#13;5:&amp;#9;pOTENTIALLY DILUTIVE SECURITIES&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;Options, warrants, and convertible debt&#13;outstanding were all considered anti-dilutive for the three months ended March 31, 2015 and 2014, due to net losses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"&gt;The following securities were not included in the diluted&#13;net loss per share calculation because their effect was anti-dilutive as of the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;52,229,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;193,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;12,514,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;57,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;15,000&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;64,808,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;330,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="text-transform: uppercase"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</tpiv:PotentiallyDilutiveSecuritiesTextBlock>
    <tpiv:PotentiallyDilutiveSecurities contextRef="From2015-01-01to2015-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; padding-right: 5.8pt; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 66%; padding-right: 0.8pt"&gt;Common stock options&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 0.8pt; text-align: right"&gt;65,000&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - equity treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;52,229,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;193,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Common stock warrants - liability treatment&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;12,514,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: right"&gt;57,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;Convertible notes&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: right"&gt;15,000&lt;/td&gt;&#13;    &lt;td style="background-color: white; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;Potentially dilutive securities&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;64,808,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 6.75pt double; padding-right: 0.8pt; text-align: right"&gt;330,000&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:PotentiallyDilutiveSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">1454000</us-gaap:CashEquivalentsAtCarryingValue>
    <tpiv:ValuationMethodology contextRef="From2015-01-01to2015-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Share Purchase Warrants&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;b&gt;Weighted Average Inputs for the Period&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Date of valuation&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;For the Quarter Ending March 31, 2015&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;&lt;b&gt;For the Quarter Ending March 31, 2014&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Dividend yield (per share)&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Strike price&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1.52&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;5.84&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Volatility (annual)&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;155.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;159.00&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;Risk-free rate&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;1.37&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;0.65&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;%&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;Contractual term (years)&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;4.85&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"&gt;3.83&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tpiv:ValuationMethodology>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-2090000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2015-01-01to2015-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2015-01-01to2015-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="INF">-2090000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2015-01-01to2015-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2015-01-01to2015-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
</xbrli:xbrl>
